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Abstract
Disease gene identification has made enormous strides in the past twenty years through functional,
positional and candidate gene approaches, and more recently by the exploitation of genome-wide
strategies. However, although pathogenic mutations in over 2000 genes have been identified as
causative of human diseases, much less is known about the relationship between the molecular
defects and mechanisms that lead to disease pathology and symptoms. Recent advances in diverse
fields such as genomics, proteomics, cell biology, as well as studies on transgenic animals have
greatly accelerated our understanding of the biochemical and cellular basis of many diseases but
much still remains to be discovered. The current challenge is to understand the molecular and
metabolic pathways by which a particular pathogenic variation leads to a specific phenotype. The
study of abnormal conditions is of crucial importance for the understanding of normal physiology
and often provides us with the rationale for the development of novel therapeutic strategies.
Editorial
PathoGenetics was created to meet the needs of the scien-
tific community for a journal focused solely on the patho-
genesis of genetic diseases. Currently studies on disease
pathogenesis can be found in a variety of different jour-
nals with different scopes but none focuses entirely on the
molecular and metabolic pathways perturbed in genetic
diseases.  PathoGenetics  is a multidisciplinary journal
which welcomes submissions from different approaches
including cell biology, biochemistry, developmental and
systems biology. Given its unique characteristics, PathoGe-
netics is likely to become the ideal journal for scientists
from different backgrounds to publish and read exciting
research on disease pathogenesis. PathoGenetics focuses on
both in vitro and in vivo studies on the cascade of events
leading from genomic lesions (i.e. either a gene mutation
or a genomic rearrangement) to disease phenotypes. The
discovery of novel molecular and metabolic pathways rel-
evant to disease pathogenesis will be given specific
emphasis.
The open access publishing model is the most effective
way of ensuring that the research we publish can be
accessed, read and built upon [1]. Once an article is
accepted it is immediately published and deposited in
PubMed ensuring dissemination of every article to a large
audience independent of an access to a journal subscrip-
tion and therefore directly benefiting the scientific com-
munity. There is evidence that an open access article is
more likely to be used and cited than one subject to sub-
scription barriers [2]. Manuscripts submitted to PathoGe-
netics will be peer-reviewed by at least two experts in the
field after initial screening by the Editors-in-Chief and a
consultation from the editorial board. We are delighted
Published: 3 November 2008
PathoGenetics 2008, 1:1 doi:10.1186/1755-8417-1-1
Received: 17 September 2008
Accepted: 3 November 2008
This article is available from: http://www.pathogenetics.com/content/1/1/1
© 2008 Ballabio et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
PathoGenetics 2008, 1:1 http://www.pathogenetics.com/content/1/1/1
Page 2 of 2
(page number not for citation purposes)
and proud that Pathogenetics has an outstanding editorial
board [3], who will work with us to ensure the high qual-
ity of the research published in this new journal.
We are committed to making this journal a success and
believe PathoGenetics will give scientists the unique oppor-
tunity to publish exciting research on the molecular mech-
anisms underlying the manifestation of disease
phenotypes and provide a forum for the understanding of
the biochemical and cellular mechanisms that underlie
genetic disease. We would like to take this opportunity to
welcoming you to this exciting new journal, and invite
you to submit your important work to PathoGenetics.
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